{"id":"https://openalex.org/W3010645285","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15","title":"Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response","display_name":"Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response","publication_year":2020,"publication_date":"2020-02-15","ids":{"openalex":"https://openalex.org/W3010645285","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15","mag":"3010645285"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs19-p3-09-15","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057580348","display_name":"Steven Jay Isakoff","orcid":"https://orcid.org/0000-0002-6677-1014","observed_orcids":["https://orcid.org/0000-0002-6677-1014"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J Isakoff","raw_affiliation_strings":["1Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035762260","display_name":"Sylvia Adams","orcid":"https://orcid.org/0000-0003-4737-1952","observed_orcids":["https://orcid.org/0000-0003-4737-1952"]},"institutions":[{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I4390039310","display_name":"NYU Langone\u2019s Laura and Isaac Perlmutter Cancer Center","ror":"https://ror.org/00sa8g751","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933","https://openalex.org/I4390039310"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sylvia Adams","raw_affiliation_strings":["2Perlmutter Cancer Center NYU Langone, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Perlmutter Cancer Center NYU Langone, New York, NY;","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I4390039310","https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090789911","display_name":"Hatem Hussein Soliman","orcid":"https://orcid.org/0000-0001-6644-2264","observed_orcids":["https://orcid.org/0000-0001-6644-2264"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hatem H Soliman","raw_affiliation_strings":["3H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051532432","display_name":"Nadine Tung","orcid":"https://orcid.org/0000-0003-1422-3734","observed_orcids":["https://orcid.org/0000-0003-1422-3734"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nadine Tung","raw_affiliation_strings":["4Beth Israel Deaconess Medical Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Beth Israel Deaconess Medical Center, Boston, MA;","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112035683","display_name":"William Thomas Barry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William T Barry","raw_affiliation_strings":["5Dana Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Dana Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063224243","display_name":"Jiani Hu","orcid":"https://orcid.org/0000-0002-2928-3169","observed_orcids":["https://orcid.org/0000-0002-2928-3169"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jiani Hu","raw_affiliation_strings":["5Dana Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Dana Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075153453","display_name":"Lorenzo Trippa","orcid":"https://orcid.org/0000-0001-5218-5666","observed_orcids":["https://orcid.org/0000-0001-5218-5666"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lorenzo Trippa","raw_affiliation_strings":["5Dana Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Dana Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012676796","display_name":"Rachel M. Deering","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Deering","raw_affiliation_strings":["1Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joanne Parker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanne Parker","raw_affiliation_strings":["6OncoPep, North Andover, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6OncoPep, North Andover, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030956732","display_name":"Hannah Park","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hannah Park","raw_affiliation_strings":["1Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063493321","display_name":"Elena F. Brachtel","orcid":"https://orcid.org/0000-0002-6109-2848","observed_orcids":["https://orcid.org/0000-0002-6109-2848"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elena F Brachtel","raw_affiliation_strings":["1Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052735318","display_name":"Leif William Ellisen","orcid":"https://orcid.org/0000-0003-0444-7910","observed_orcids":["https://orcid.org/0000-0003-0444-7910"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leif W Ellisen","raw_affiliation_strings":["1Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061431553","display_name":"Mariano Severgnini","orcid":"https://orcid.org/0000-0001-6783-8500","observed_orcids":["https://orcid.org/0000-0001-6783-8500"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mariano Severgnini","raw_affiliation_strings":["5Dana Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Dana Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075344817","display_name":"Doris Peterkin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Doris Peterkin","raw_affiliation_strings":["6OncoPep, North Andover, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6OncoPep, North Andover, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M Tolaney","raw_affiliation_strings":["5Dana Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Dana Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"4_Supplement","first_page":"P3","last_page":"09"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.6807000041007996,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.6807000041007996,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.2653999924659729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.04479999840259552,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9390000104904175},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.7419999837875366},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.8669999837875366},{"id":"https://openalex.org/keywords/adjuvant-immunotherapy","display_name":"adjuvant immunotherapy","score":0.8370000123977661},{"id":"https://openalex.org/keywords/peptide-vaccine","display_name":"peptide vaccine","score":0.652999997138977},{"id":"https://openalex.org/keywords/xbp1","display_name":"XBP1","score":0.890999972820282},{"id":"https://openalex.org/keywords/syndecan-1","display_name":"syndecan-1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hla-a2","display_name":"HLA-A2","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.5709999799728394},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.6949999928474426},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7570000290870667},{"id":"https://openalex.org/keywords/vaccine-safety-and-tolerability","display_name":"vaccine safety and tolerability","score":0.6600000262260437},{"id":"https://openalex.org/keywords/immune-response","display_name":"immune response","score":0.6110000014305115},{"id":"https://openalex.org/keywords/local-regional-recurrence","display_name":"local-regional recurrence","score":0.6029999852180481},{"id":"https://openalex.org/keywords/montanide","display_name":"Montanide","score":0.47200000286102295}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8144925236701965},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6141666769981384},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.5523885488510132},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.471365362405777},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4587441384792328},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4572337567806244},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4524747431278229},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.44837722182273865},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.41920697689056396},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3359290659427643},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3171880841255188},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2556201219558716}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs19-p3-09-15","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2624253981","https://openalex.org/W4220815396","https://openalex.org/W2947299562","https://openalex.org/W4322769719","https://openalex.org/W4220927199","https://openalex.org/W2737784234","https://openalex.org/W3008580471","https://openalex.org/W3195849621","https://openalex.org/W2791534052","https://openalex.org/W2939685075"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"eTNBC":[2,571],"remains":[3],"at":[4,100,109,209,214,240,324,446,478],"high":[5],"risk":[6],"for":[7,82,187,202,269,347,439,524,615],"recurrence":[8,132,554],"despite":[9],"modern":[10],"(neo)adjuvant":[11],"chemotherapy.":[12],"Immunotherapy":[13],"with":[14,40,95,108,130,139,157,171,279,509,534,570,572],"checkpoint":[15],"inhibition":[16],"is":[17,35,564],"active":[18],"in":[19,54,78,153,251,274,305,372,473,491,506,516,568,591,598,620,680],"early":[20,682],"and":[21,24,50,67,72,97,155,163,174,213,219,227,261,282,301,321,337,358,406,417,425,502,555,566,589,604,692],"metastatic":[22,552],"TNBC,":[23],"vaccines":[25],"may":[26],"further":[27],"induce":[28],"host":[29],"immune":[30,68,203,236,288,350,465,513,610,626,693],"response.":[31,627],"PVX-410":[32,671],"(PVX,":[33],"OncoPep)":[34],"a":[36,61,181,194,244,283,462,535,548,624],"novel":[37],"tetra-peptide":[38],"vaccine":[39,176,673],"3":[41,339,415,422],"of":[42,70,113,119,135,148,166,254,264,277,294,449,458,494,529,539,543,670,698],"the":[43,172,252,262,292,304,373,440,447,492,505,527,699],"4":[44,111,432,542],"antigens":[45],"(XBP1":[46],"[2":[47],"splice":[48],"variants]":[49],"CD138)":[51],"commonly":[52],"overexpressed":[53],"TNBC.":[55],"Here":[56],"we":[57],"present":[58],"results":[59],"from":[60],"phase1b":[62],"study":[63,89,127,179,669],"evaluating":[64],"safety,":[65],"tolerability":[66],"response":[69,204,237,289,437,466,471,514,579,694],"PVX":[71,150,234,270,280,354,463,510,561,583,599,613],"durvalumab":[73,675],"(DUR)":[74,676],"as":[75,243,594,677],"adjuvant":[76,114,678],"therapy":[77,122,679],"eTNBC.":[79],"Methods:":[80],"Eligibility":[81],"this":[83],"phase":[84,667],"1b":[85,668],"multi-center,":[86],"single":[87],"arm":[88],"included:":[90],"HLA-A2+":[91,681],"female":[92],"patients":[93,460,520],"(pts)":[94],"TNBC":[96],"tumor":[98],"size":[99],"least":[101,110],"1":[102,328,330,359,418],"cm":[103],"or":[104,115,246,433,551],"node":[105],"positive;":[106],"treatment":[107],"cycles":[112],"neoadjuvant":[116],"chemotherapy;":[117],"completion":[118],"all":[120,352,474,517],"planned":[121,353],"1-6":[123],"months":[124,619],"prior":[125],"to":[126,185,365,454,485,612,617,689],"entry.":[128],"Pts":[129,144],"local-regional":[131],"without":[133],"evidence":[134],"distant":[136],"metastases":[137],"treated":[138],"curative":[140],"were":[141,200,356,370,429],"also":[142],"eligible.":[143],"received":[145],"6":[146,182,374,479,618],"doses":[147,165,355],"800ug":[149],"(subcutaneously)":[151],"emulsified":[152],"Montanide":[154],"co-administered":[156],"Hiltonol":[158],"(IM)":[159],"every":[160],"2":[161,164,333,556],"weeks,":[162],"1500mg":[167],"DUR":[168,360,563],"(IV)":[169],"concurrent":[170],"4th":[173],"6th":[175],"treatments.":[177],"The":[178,222,229,377],"included":[180,291],"pt":[183,196,375,412,419],"run-in":[184],"assess":[186,690],"dose":[188,361],"limiting":[189],"toxicity":[190,366],"(DLT),":[191],"followed":[192],"by":[193,596],"14":[195,242,335,349],"expansion.":[197],"Blood":[198],"samples":[199,476],"collected":[201],"assessment":[205,238,438,515],"via":[206],"flow":[207,284],"cytometry":[208],"week":[210,241,348,455],"0":[211],"(Baseline)":[212],"weeks":[215],"6,":[216],"10,":[217],"14,":[218,456],"24":[220],"post-treatment.":[221],"primary":[223],"objective":[224,232],"was":[225,233,316,362],"safety":[226,691],"tolerability.":[228],"key":[230],"secondary":[231],"specific":[235,464],"defined":[239,468],"2-fold":[245],"greater":[247],"change":[248],"over":[249,489],"baseline":[250,453,490],"proportion":[253,263,293],"CD3+CD8+":[255,265,295,495],"T":[256,266,296,496,586,607,641],"cells":[257,267,297,497],"that":[258,498,582],"expressed":[259,499],"IFN\u03b3":[260],"positive":[268,606],"tetramers":[271],"following":[272,303,504],"an":[273],"vitro":[275,306,507],"stimulation":[276,508],"PBMC":[278],"peptides":[281],"cytometric":[285],"determination.":[286],"Other":[287],"assessments":[290],"expressing":[298],"TNF\u03b1,":[299,500,602],"IL-2,":[300,501],"CD137":[302,503,605],"peptide":[307],"stimulation.":[308],"Results:":[309],"Among":[310,343],"22":[311,544],"pts":[312,345,443,483,546,569,593],"enrolled,":[313],"median":[314,536],"age":[315],"48":[317],"yrs":[318],"(range":[319],"34-68)":[320],"anatomical":[322],"stage":[323,683],"diagnosis":[325],"was:":[326],"Stage":[327,332,338],"=":[329,334,340],"(4.5%),":[331],"(64%),":[336],"7":[341],"(32%).":[342],"20":[344,518],"evaluable":[346,519],"response,":[351],"given,":[357],"held":[363],"due":[364],"(tox).":[367],"No":[368],"DLTs":[369],"observed":[371,595],"run-in.":[376],"most":[378,482,621],"common":[379],"adverse":[380],"events":[381],"(all":[382],"grades)":[383],"include:":[384],"injection":[385],"site":[386],"reaction":[387],"(96%),":[388],"flu-like":[389],"symptoms,":[390],"fatigue":[391],"(41%":[392],"each),":[393,397],"arthralgia,":[394],"pruritis":[395],"(36%":[396],"ALT":[398,426],"elevation":[399,408],"(32%),":[400],"myalgia":[401],"(27%),":[402],"pain,":[403],"diarrhea,":[404],"AST":[405,424],"amylase":[407],"(23%":[409],"each).":[410],"One":[411],"had":[413,420,487,547],"grade":[414,421,431],"diarrhea":[416],"hyponatremia,":[423],"elevation.":[427],"There":[428],"no":[430,573],"5":[434],"events.":[435],"Immune":[436,470,578],"first":[441],"12":[442,459],"are":[444],"available":[445],"time":[448,528],"abstract":[450],"submission.":[451],"Comparing":[452],"10":[457],"demonstrated":[461],"(as":[467],"above).":[469],"persisted":[472,614],"patient":[475],"tested":[477,484],"months.":[480],"Additionally,":[481],"date":[486],"increases":[488,597],"proportions":[493],"peptides.":[511],"Final":[512],"will":[521],"be":[522],"updated":[523],"presentation.":[525],"At":[526],"data":[530,580],"cut":[531],"off":[532],"(4/29/19),":[533],"follow":[537],"up":[538,616],"15.4":[540],"months,":[541],"(18%)":[545],"local":[549],"(1)":[550],"(3)":[553],"(9%)":[557],"have":[558],"died.":[559],"Conclusions:":[560],"plus":[562,674],"safe":[565],"tolerable":[567],"new":[574],"unexpected":[575],"toxicities":[576],"identified.":[577],"demonstrate":[581],"induces":[584],"antigen-specific":[585],"cell":[587],"expansion":[588],"activation":[590],"these":[592],"tetramer,":[600],"IFN\u03b3,":[601],"IL-2":[603],"cells.":[608],"These":[609],"responses":[611],"patients,":[622],"indicating":[623],"prolonged":[625],"Citation":[628],"Format:":[629],"Steven":[630],"J":[631],"Isakoff,":[632],"Sylvia":[633],"Adams,":[634],"Hatem":[635],"H":[636],"Soliman,":[637],"Nadine":[638],"Tung,":[639],"William":[640],"Barry,":[642],"Jiani":[643],"Hu,":[644],"Lorenzo":[645],"Trippa,":[646],"Rachel":[647],"Deering,":[648],"Joanne":[649],"Parker,":[650],"Hannah":[651],"Park,":[652],"Elena":[653],"F":[654],"Brachtel,":[655],"Leif":[656],"W":[657],"Ellisen,":[658],"Mariano":[659],"Severgnini,":[660],"Doris":[661],"Peterkin,":[662],"Sara":[663],"M":[664],"Tolaney.":[665],"A":[666],"(PVX)":[672],"triple":[684],"negative":[685],"breast":[686],"cancer":[687],"(eTNBC)":[688],"[abstract].":[695],"In:":[696],"Proceedings":[697],"2019":[700,706],"San":[701,709],"Antonio":[702],"Breast":[703],"Cancer":[704,715],"Symposium;":[705],"Dec":[707],"10-14;":[708],"Antonio,":[710],"TX.":[711],"Philadelphia":[712],"(PA):":[713],"AACR;":[714],"Res":[716],"2020;80(4":[717],"Suppl):Abstract":[718],"nr":[719],"P3-09-15.":[720]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2021,"cited_by_count":3}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-03-23T00:00:00"}